Go Pro
NASDAQ:VIVE

Viveve Medical (VIVE) Stock Price, News & Analysis

Viveve Medical logo
$0.0002 0.00 (0.00%)
As of 08/28/2026 11:44 AM Eastern

About Viveve Medical Stock (NASDAQ:VIVE)

Advanced

Key Stats

Today's Range
$0.0002
$0.0002
50-Day Range
N/A
52-Week Range
$0.0001
$0.0009
Volume
1,100 shs
Average Volume
2,662 shs
Market Capitalization
$434.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Viveve Medical, Inc. is a medical technology company focused on the development and commercialization of non-invasive solutions for women’s intimate health. The company’s flagship offering, the Viveve System, employs proprietary cryogen-cooled monopolar radiofrequency energy to gently heat and remodel vaginal tissue. This technology is designed to address conditions such as vaginal laxity and associated symptoms, offering a single-treatment protocol that can be performed in a clinical setting without the need for anesthesia.

Regulatory clearances, including U.S. Food and Drug Administration (FDA) 510(k) authorization, underpin the safety profile of the Viveve System. The company’s research and development efforts have centered on optimizing treatment parameters and expanding the application of its proprietary energy-delivery platform. Viveve Medical also provides training and support to healthcare professionals in aesthetic, urogynecology and gynecology practices to ensure consistent clinical outcomes and patient satisfaction.

Since its founding in 2009 and subsequent initial public offering on the NASDAQ in 2015 under the ticker VIVE, Viveve Medical has pursued a global commercialization strategy. The company’s products are available in key markets across North America, Latin America, Europe and Asia through a combination of direct sales and distribution partnerships. By focusing exclusively on women’s intimate wellness, Viveve Medical aims to establish a differentiated position within the broader medical aesthetics and women’s health markets.

AI Generated. May Contain Errors.

Receive VIVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIVE Stock News Headlines

Viveve Medical Inc.
Viveve Medical Inc (VIVE)
These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI
Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture after OpenAI, one some say could be 500 times bigger than ChatGPT. Test staff are said to be bound by law to keep details secret, and three lesser-known stocks may be tied to this next chapter in AI.tc pixel
Vaginal Rejuvenation Is Big Business
VIVE Viveve Medical, Inc.
See More Headlines

VIVE Stock Analysis - Frequently Asked Questions

Viveve Medical's stock was trading at $0.0001 at the start of the year. Since then, VIVE shares have increased by 100.0% and is now trading at $0.0002.

Viveve Medical, Inc. (NASDAQ:VIVE) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.09. The business had revenue of $1.62 million for the quarter.

Viveve Medical (VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group served as the underwriters for the IPO and Maxim Group was co-manager.

Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), NIO (NIO) and Western Digital (WDC).

Company Calendar

Last Earnings
11/11/2021
Today
8/30/2026
Next Earnings (Estimated)
8/31/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:VIVE
Previous Symbol
OTCMKTS:PLCSD
CIK
879682
Employees
70
Year Founded
2005

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$6.83 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,170,000
Free Float
N/A
Market Cap
$434.00
Optionable
Not Optionable
Beta
-0.08

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:VIVE) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners